



European Hematology Association Disclosure Form 2016-2017

Instructions

All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information. If in doubt, err on the side of over-reporting. The form expires on the day of the business meeting at EHA Annual Congress in June 2017.

Financial relationship: to financially benefit, or to have benefited in the past 12 months, by receiving salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interest, research support or any other financial benefit from any commercial entity which has (potentially or perceived) interests that may conflict with those of EHA.

Direct financial relationship: you benefit.

Indirect financial relationship: the institute or organization of which you are employee (or otherwise have a financial relation with) benefits.

Personal details: enter your full name, your organization name, mail and e-mail addresses on which you would like to be contacted regarding this declaration.

Sign and attach this form

Publishing: your disclosure may be published.

Please declare any financial relationship

☐ I have no financial relationship(s) to disclose

☐ I have one or more financial relationship(s) to disclose, namely:

Name of Company	Direct (yes/no)	Indirect (yes/no)
add rows if needed		

Please enter your personal details

Name
Organization/institute/company
Work (postal) address
E-mail address
Function(s) at EHA

I declare that I have, to the best of my knowledge, disclosed any financial relationship.

Signature:

Date:



Frequently Asked Questions

Q: I have no affiliations to disclose, do I have to fill this in?

A: Yes. Confirm that you have no financial relationships to disclose.

Q: What is a financial relationship?

A: It is a relationship with a commercial entity that has (potentially or perceived) interests that conflict with those of EHA (e.g. pharmaceutical company) in which you, or the organization or institute you work for, receive financial benefit - or have received benefit in the past 12 months.

Q: Do you have some examples of financial relationships?

A: Yes. Examples are salary, royalty, intellectual property rights, remuneration of a book chapter, consulting fees, honoraria, ownership interest, shares (except independently managed investment funds or pension schemes that are not exclusively based on the pharmaceutical sector), research support, (principal) investigator, corporate sponsorship, educational grants, etc. etc. Any other financial benefit from any commercial entity which has (potentially or perceived) interests that may conflict with those of EHA also constitutes a financial relationship.

Q: I think I may have a financial relationship but it is not listed above. What should I do?

A: Err on the side of over-reporting. It is better to disclose redundant relationships than it is risk omitting relevant relationships. Furthermore, the onus of deciding the relevance of a relationship is not on you but on the EHA Board.

Q: What is a direct financial relationship?

A: A direct financial relationship is where you benefit. Examples are: salary, royalty, intellectual property rights, remuneration of a book chapter, consulting fees, honoraria, ownership interest, or shares (except independently managed investment funds or pension schemes that are not exclusively based on the pharmaceutical sector).

Q: What is an indirect financial relationship?

A: An indirect financial relationship is where the organization or institute you are employed benefits. Examples are: research support, (principal) investigator, corporate sponsorship, or educational grants.

Q: Are there any direct or indirect financial relationships that I do not have to report?

A: Yes. You do not have to report remuneration from industry for clinical trial subjects. You do not have to report shares of independently managed investment funds or pension schemes that are not exclusively based on the pharmaceutical sector.

Q: What is the validity of this form?

A: The European Hematology Association Disclosure Form will be part of the information package that is used by the review committee in the selection.